Limits...
Immunologic biomarkers for clinical and therapeutic management of psoriasis.

Cordiali-Fei P, Bianchi L, Bonifati C, Trento E, Ruzzetti M, Francesconi F, Bultrini S, D'Agosto G, Bordignon V, Francavilla V, Tripiciano A, Chiricozzi A, Campione E, Cavallotti C, Orlandi A, Berardesca E, Di Carlo A, Chimenti S, Ensoli F - Mediators Inflamm. (2014)

Bottom Line: Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks.IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes.T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology & Microbiology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

ABSTRACT

Background: The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis.

Aims: To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis.

Methods: An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-α agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment.

Results: Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression.

Conclusions: Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.

Show MeSH

Related in: MedlinePlus

Individual levels (dots) and median values (line) of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected at baseline (T0), before therapy initiation.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4129379&req=5

fig1: Individual levels (dots) and median values (line) of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected at baseline (T0), before therapy initiation.

Mentions: The measurement of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected before therapy showed an increase in the levels of IL-6, IL-8, and IL-22, as shown in Figure 1. Consequently, these cytokines were assessed during the therapeutic follow-up. The results, summarized in Figure 2, showed a significant reduction of IL-6 and IL-22 induced by therapy after 24 weeks of treatment in all patient groups, while the levels of IL-8 were not significantly modified. The reduction of IL-22 was found in all treatment groups, while IL-6 reduction was statistically significant only when the analysis was performed considering all patient groups.


Immunologic biomarkers for clinical and therapeutic management of psoriasis.

Cordiali-Fei P, Bianchi L, Bonifati C, Trento E, Ruzzetti M, Francesconi F, Bultrini S, D'Agosto G, Bordignon V, Francavilla V, Tripiciano A, Chiricozzi A, Campione E, Cavallotti C, Orlandi A, Berardesca E, Di Carlo A, Chimenti S, Ensoli F - Mediators Inflamm. (2014)

Individual levels (dots) and median values (line) of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected at baseline (T0), before therapy initiation.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4129379&req=5

fig1: Individual levels (dots) and median values (line) of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected at baseline (T0), before therapy initiation.
Mentions: The measurement of TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IL-17, and IL-22 in sera collected before therapy showed an increase in the levels of IL-6, IL-8, and IL-22, as shown in Figure 1. Consequently, these cytokines were assessed during the therapeutic follow-up. The results, summarized in Figure 2, showed a significant reduction of IL-6 and IL-22 induced by therapy after 24 weeks of treatment in all patient groups, while the levels of IL-8 were not significantly modified. The reduction of IL-22 was found in all treatment groups, while IL-6 reduction was statistically significant only when the analysis was performed considering all patient groups.

Bottom Line: Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks.IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes.T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology & Microbiology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

ABSTRACT

Background: The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-α inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis.

Aims: To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis.

Methods: An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-α agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment.

Results: Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression.

Conclusions: Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.

Show MeSH
Related in: MedlinePlus